- Home
- MRUS
MRUS
Merus N.V.
as 12-18-2024 10:40am EST
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
| Founded: | 2003 | Country: | Netherlands |
| Employees: | N/A | City: | 3584 CM UTRECHT |
| Market Cap: | 2.9B | IPO Year: | 2016 |
| Target Price: | $87.92 | AVG Volume (30 days): | 635.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.95 - $61.61 | Next Earning Date: | 10-31-2024 |
| Revenue: | $35,932,000 | Revenue Growth: | -21.33% |
| Revenue Growth (this year): | -14.39% | Revenue Growth (next year): | 57.37% |
Latest Merus N.V. News
MRUS Breaking Stock News: Dive into MRUS Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
GlobeNewswire
2 days ago
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
Insider Monkey
8 days ago
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
GlobeNewswire
11 days ago
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Benzinga
13 days ago
Merus Scores Its First FDA Approval For Lung Cancer Drug
Clinical Trials Arena
13 days ago
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
MT Newswires
14 days ago
Merus Gets US FDA Approval for Bizengri in Advanced Pancreatic, Lung Cancers
GlobeNewswire
14 days ago
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
Compare MRUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRUS Merus N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.